alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 126–150 of 247 studies in Research Square (page 6 of 10) · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Caregiving experiences of older-adult informal family caregivers for older adults with comorbid dementia and physical disability: A qualitative study using the caregiving stress-process model

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-14

Five core themes and fifteen corresponding sub-themes were extracted from interview transcripts: (1) Structural caregiving context, including family structural constraints, the influence of filial piety culture, and insufficient aged-care supply; (2) Multiple caregiving stressors, covering primary care burden, independent care decision-making pressure, restricted social engagement, and intra-family conflicts; (3) Limited buffering support resources, involving inadequate formal care services, insufficient informal assistance from relatives, and individual psychological coping strategies; (4) Negative caregiving experiences, including persistent physical exhaustion and sustained emotional depletion; (5) Dual perceptions of caregiving outcomes, consisting of emotional gains from kinship bonding, resistance to institutional care, and long-term anxiety about future care arrangements. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

Newly diagnosed postoperative depression and incident dementia after major surgery: a Korean nationwide retrospective cohort study

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-30

Newly diagnosed postoperative depression was associated with increased dementia risk, particularly in patients aged < 65 years, supporting prospective evaluation as a potential marker of long-term cognitive risk. 4 key findings →

Design: cohort study Participants: 424,637 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Caregiver burden and mood changes among unpaid caregivers of older adults living with dementia

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-25

Depressive and anxiety symptoms were more pronounced among caregivers with longer caregiving duration (p = 0.01; p = 0.001) and those living with the care recipient (p = 0.04; p = 0.02). 4 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

Brain Iron Accumulation and Its Cognitive and Olfactory Correlates in Late-Life Depression

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-10

Late-life depression (LLD) is associated with cognitive impairment, olfactory dysfunction and dementia risk, while brain iron accumulation has been linked to depressive symptoms, cognitive impairment and Alzheimer’s disease progression. 3 key findings →

Participants: 38 Evidence: low

Full summary, score breakdown and related studies → Original source

Comparative comorbidity burden in hospitalized primary Parkinson's disease and secondary parkinsonism: a cross-sectional study from Southwest China

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-09

The study evaluated 1,457 PD patients (1,050 primary; 407 secondary) alongside 2,100 matched non-PD controls. 5 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source

Panel-Gene Transcriptomic Associations and Published-Variant Architecture in Parkinson Disease

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-22

Parkinson disease (PD) was examined in four primary adult-brain GEO cohorts (GSE49036, GSE20141, GSE8397, GSE7621) using a frozen 468-gene redox, metal, xenobiotic, and barrier panel. 1 key finding →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source

Association between urban green space coverage and incident Alzheimer’s disease among older adults in metropolitan South Korea: a population-based retrospective cohort study

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-14

Higher UGS coverage was associated with a lower risk of incident AD among older adults in urban South Korea. 4 key findings →

Design: cohort study Participants: 95,822 Evidence: moderate

Full summary, score breakdown and related studies → Original source

A Study on the Association Between the Course of Heart Failure and Cognitive Function in Older Adults: Based on Data from the 2011–2014 National Health and Nutrition Examination Survey

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-02

The 2,885 participants had a mean age of 69.5 years. 4 key findings →

Design: longitudinal study Participants: 2,885 Evidence: moderate

Full summary, score breakdown and related studies → Original source

Evidence that the perinatal maternal microbiome mediates metabolite signaling programs that drive sex-specific microglial metabolic alterations and Alzheimer’s disease susceptibility

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-23

Maternal microbiome-dependent programming of neuroimmune and metabolic pathways during early development may critically shape sex-specific susceptibility to Alzheimer’s disease (AD) later in life. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source

GPR6 Protects Medial Entorhinal Cortex in 5×FAD Mice from Early Pathology in Alzheimer’s Disease

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-22

Alzheimer’s disease (AD) is characterized by progressive memory decline, with the medial entorhinal cortex (MEC) representing an early vulnerable hub for spatial cognition. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Multi-omics framework prioritizes RNA Methylation Modification Genes in Alzheimer's Disease and Functional Validation of ZFP36 in Regulating Neuroinflammation

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-21

Alzheimer’s disease (AD) is a progressive neurodegenerative disorder, in which epitranscriptomic modifications, especially RNA methylation, may exert crucial regulatory effects. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Multi-Omics Analysis Reveals Molecular Responses of Alkaloid Content Variations in Lycoris radiata Across Different Locations

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-09-08

The Amaryllidaceae geophyte Lycoris radiata is a primary botanical source of high-value medicinal alkaloids, including the Alzheimer’s therapeutic galanthamine. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Gut microbiota mediates the association between aging and cognitive function: evidence from a population-based Kyotango study linking diet, Bifidobacterium, and Mini-Mental State Examination (MMSE) score

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-08-04

Our findings provide evidence that age-related changes in the gut microbiota, particularly reductions in Bifidobacterium , partially mediate cognitive decline in older adults. 5 key findings →

Design: cross-sectional Participants: 578 Evidence: low

Full summary, score breakdown and related studies → Original source

Spermine inhibits ferroptosis in vascular dementia rats by intervening Nrf2/SLC7A11/GPX4 expression in chondriosome

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-09

Spermine exerts neuroprotective effects in VaD by inhibiting TRPM2-mediated oxidative stress and activating the Nrf2/SLC7A11/GPX4 pathway, thereby suppressing ferroptosis. 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source

Inflammatory biomarker candidates in dementia with Lewy bodies: diagnostic classification, clinical associations, and survival

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-11-01

Dementia with Lewy bodies (DLB) is a common neurodegenerative dementia that remains difficult to distinguish clinically from Alzheimer's disease (AD) and related disorders because of overlapping clinical features and frequent mixed pathology. 4 key findings →

Participants: 20 Evidence: low

Full summary, score breakdown and related studies → Original source

Systematic identification of perioperative neurocognitive disorder related biomarkers in Alzheimer’s disease and development of machine learning-based diagnostic models

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-16

Alzheimer’s disease (AD) is a widely prevalent neurodegenerative disorder characterized by progressive cognitive impairment and neuropathological alterations. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

Selective vulnerability: validation of atypical neurodegenerative disease variants in histopathological reference cohorts

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-16

Conventional, cohort-based staging exhibited profound topographical inversion, yielding negative correlations for TDP-43 ( ρ = -0.9113, p < 0.001) and α-synuclein ( ρ = -0.8660, p = 0.003) sub-cohorts. 5 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source

Human multiscale transcriptomics identifies the NLRP3 inflammasome as a convergent druggable target in Alzheimer’s disease: validation with dimethyl itaconate in 5xFAD mice

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Research Square 2026-10-07

Neuroinflammation is a hallmark of Alzheimer’s disease (AD); however, which neuroinflammatory effectors are consistently altered across independent human cohorts, brain regions, and microglial states—and can be engaged by available compounds—remains incompletely defined. 4 key findings →

Design: meta-analysis Evidence: high

Full summary, score breakdown and related studies → Original source

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed